This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
-
California Cancer Associates for Research and Excellence, Inc., Encinitas, California, United States, 92024
University of California, San Diego (UCSD) - Medical Center, La Jolla, California, United States, 92037
University of California - Irvine Medical Center, Orange, California, United States, 92868
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States, 80218
Florida Cancer Specialists, Sarasota, Florida, United States, 34232
Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States, 48201
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States, 89169
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021
Stephenson Cancer Center (Oklahoma University), Oklahoma City, Oklahoma, United States, 73104
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
BicycleTx Limited,
Meredith McKean, MD, MPH, STUDY_CHAIR, Sarah Cannon and HCA Research Institute
2025-10-01